Latest Breaking News On - நோய் மையம் - Page 6 : comparemela.com

New Alzheimer’s drug Aducanumab – cost, side effects, timeline and other questions answered Patients and their families are starting to inquire about the new Alzheimer’s drug approved this week by the US Food and Drug Administration. Shipments of the medication are expected to go out in just a couple of weeks. Hospitals are on tap to administer treatment when needed. And there is serious division in the FDA, especially around the drug’s effectiveness. Aducanumab, to be sold under the brand name Aduhelm, was approved to treat patients with Alzheimer’s disease against the recommendation of an FDA advisory committee that concluded last year there is not enough evidence to support approval of the treatment. The FDA has not approved a novel therapy for Alzheimer’s disease since 2003.

University of southern californiaUnited statesLon schneiderChirfi guindoJulia biernotMemorial healthcare institute for neuroscienceNational association of freeDrug administrationCentral nervous system drugs advisory committeeVeterans health administrationUniversity of maryland school medicineCalifornia alzheimer disease centerUniversity of maryland medical centerInstitute for neuroscienceMemorial healthcareRany aburashed